Explore Business Standard
Panacea Biotec
Panacea Biotec Ltd on Thursday said it will supply bivalent oral polio vaccines worth Rs 127.2 crore to the Central Medical Services Society, Ministry of Health and Family Welfare. In a regulatory filing, Panacea Biotec said the Central Medical Services Society (CMSS) has accepted the company's offer for supply of bivalent oral polio vaccine against the tender issued by it through a Letter of Acceptance (LOA) dated October 8, 2025. "As per the LOA, the company will supply the vaccine worth Rs 127.2 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA," it added.
US International Development Finance Corporation (DFC) has committed a long-term loan of up to USD 20 million to Panacea Biotec, the company said on Thursday. Panacea is expanding the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix to meet future demand from UN agencies and public health organisations. DFC has agreed to provide a long-term loan of up to USD 20 million to the company to help finance this project, the biotechnology firm said in a regulatory filing. DFC's financing will enable Panacea Biotec to expedite the completion of the ongoing expansion and supply the hexavalent vaccine to UN agencies for childhood immunisation globally, it added. "Our hexavalent vaccine EasySix, which meets the highest standards of safety and efficacy, will have a meaningful impact on the lives of millions of newborns in the developing world," Panacea Biotec Chairman and MD Rajesh Jain said. DFC Deputy CEO Nisha Biswal said the organisation's partnersh
Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac
Panacea Biotec Ltd on Thursday said the US health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld. The US Food and Drug Administration (USFDA) had inspected the Baddi unit of its subsidiary, Panacea Biotec Pharma Ltd (PBPL) from May 30 to June 8, 2022. Subsequently, the USFDA issued Form 483 with eight observations which are related to improvements in existing procedures and are addressable, Panacea Biotec said in a regulatory filing. According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company said it has "now received a communication from the USFDA indicating the inspection classification .